Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant964 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT04071223 | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study | active not recruiting | Phase 2 | 98 | National Cancer Institute (NCI)NIH |
| 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT04640623 | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy(SunRISe-1) | active not recruiting | Phase 2 | 220 | Janssen Research & Development, LLCINDUSTRY | 16 | Sep 25, 2026 | clinicaltrials |
| NCT05316155 | Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | active not recruiting | Phase 1 / Phase 2 | 235 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT03635892 | A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04506554 | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | active not recruiting | Phase 2 | 81 | Fox Chase Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies(PETRA) | active not recruiting | Phase 1 / Phase 2 | 702 | AstraZenecaINDUSTRY | 14 | Sep 21, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT04940299 | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | active not recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05831891 | Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 2 | 40 | RenJi HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT05012371 | Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer | active not recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06708949 | A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC) | active not recruiting | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06480565 | A Phase 1/2 Trial of ADI-270 in ccRCC | active not recruiting | Phase 1 / Phase 2 | 60 | Adicet TherapeuticsINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT00365157 | Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction | active not recruiting | Phase 1 / Phase 2 | 171 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05411081 | Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial | active not recruiting | Phase 2 | 200 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04917809 | A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer | active not recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04006522 | 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma | active not recruiting | Phase 2 | 46 | James BrugarolasOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03473743 | A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer | active not recruiting | Phase 1 / Phase 2 | 125 | Janssen Research & Development, LLCINDUSTRY | 13 | Aug 28, 2026 | clinicaltrials |
| NCT03595124 | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | active not recruiting | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04579380 | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | active not recruiting | Phase 2 | 217 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 8 | Aug 21, 2026 | clinicaltrials |
| NCT05468697 | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | active not recruiting | Phase 1 / Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT05335941 | A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | active not recruiting | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06284564 | A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) | active not recruiting | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT01038778 | Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03203473 | Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) | active not recruiting | Phase 2 | 85 | Toni Choueiri, MDOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04164082 | Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | active not recruiting | Phase 2 | 161 | National Cancer Institute (NCI)NIH | 3 | Aug 11, 2026 | clinicaltrials |
| NCT04179162 | Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment | active not recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05805501 | A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | active not recruiting | Phase 2 | 199 | Hoffmann-La RocheINDUSTRY | 9 | Aug 10, 2026 | clinicaltrials |
| NCT05137262 | A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder | active not recruiting | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05868265 | A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract | active not recruiting | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06444880 | Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03459846 | A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)(BAYOU) | active not recruiting | Phase 2 | 154 | AstraZenecaINDUSTRY | 7 | Aug 5, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT03047213 | Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations | active not recruiting | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03237780 | Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03284385 | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | active not recruiting | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03854474 | Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma | active not recruiting | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT03693014 | A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors | active not recruiting | Phase 2 | 69 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02306954 | Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer | active not recruiting | Phase 2 | 84 | Providence Health & ServicesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04413123 | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | active not recruiting | Phase 2 | 60 | Bradley A. McGregor, MDOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04706598 | Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment | active not recruiting | Phase 1 / Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05531123 | Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer | active not recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03504163 | Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] | active not recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT01217931 | Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial | active not recruiting | Phase 2 | 180 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03541902 | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | active not recruiting | Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
Data updated 7 hours agoSource updated Sep 29, 2026source: clinicaltrials